Benjamin J Bivona
Overview
Explore the profile of Benjamin J Bivona including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun Y, Meyers B, Czako B, Leonard P, Mseeh F, Harris A, et al.
Cancer Res
. 2020 Sep;
80(21):4840-4853.
PMID: 32928921
Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full activation of the MAPK pathway. SHP2...
2.
Bivona B, Takai S, Seth D, Satou R, Harrison-Bernard L
Physiol Rep
. 2019 Dec;
7(24):e14302.
PMID: 31872559
Chymase released from mast cells produces pro-fibrotic, inflammatory, and vasoconstrictor agents. Studies were performed to test the hypothesis that chronic chymase inhibition provides a renal protective effect in type 2...
3.
Park S, Bivona B, Harrison-Bernard L
Am J Physiol Renal Physiol
. 2018 Feb;
314(6):F1197-F1204.
PMID: 29412691
We have previously reported significant increases in neuronal nitric oxide synthase (NOS) immunostaining in renal arterioles of angiotensin type 1A receptor (AT1A) knockout mice, and in arterioles and macula densa...
4.
Perricone A, Bivona B, Jackson F, Vander Heide R
J Am Heart Assoc
. 2013 Oct;
2(5):e000457.
PMID: 24080910
Background: Our laboratory has previously demonstrated the importance of a cytoskeletal-based survival signaling pathway using in vitro models of ischemia/reperfusion (IR). However, the importance of this pathway in mediating stress-elicited...
5.
Harrison-Bernard L, de Garavilla L, Bivona B
Ochsner J
. 2013 Mar;
13(1):49-55.
PMID: 23532714
Background: Diabetic nephropathy (DN) is associated with enhanced renal, plasma, and urinary endothelin (ET)-1 levels. Chymase cleaves Big ET-1 (1-38) to ET-1 (1-31), which is further cleaved by neutral endopeptidase...
6.
Park S, Bivona B, Ford Jr S, Xu S, Kobori H, de Garavilla L, et al.
Hypertension
. 2012 Dec;
61(2):465-71.
PMID: 23213190
Our previous work supports a major role for angiotensin-converting enzyme (ACE)-independent intrarenal angiotensin (ANG) II formation on microvascular function in type 2 diabetes mellitus. We tested the hypothesis that there...
7.
Bivona B, Park S, Harrison-Bernard L
Am J Physiol Renal Physiol
. 2010 Dec;
300(3):F618-25.
PMID: 21147841
Diabetic nephropathy is a major cause of end-stage renal disease worldwide. The current studies were performed to determine the later stages of the progression of renal disease in type II...
8.
Park S, Bivona B, Kobori H, Seth D, Chappell M, Lazartigues E, et al.
Am J Physiol Renal Physiol
. 2009 Oct;
298(1):F37-48.
PMID: 19846569
Combination therapy of angiotensin-converting enzyme (ACE) inhibition and AT(1) receptor blockade has been shown to provide greater renoprotection than ACE inhibitor alone in human diabetic nephropathy, suggesting that ACE-independent pathways...
9.
Park S, Bivona B, Feng Y, Lazartigues E, Harrison-Bernard L
Am J Physiol Renal Physiol
. 2008 Aug;
295(5):F1504-11.
PMID: 18753291
The db/db mouse is a genetic model of type 2 diabetes that exhibits progressive renal disease. Obesity, hyperglycemia, and albuminuria (822 +/- 365 vs. 28 +/- 8 microg/day) are evident...
10.
Park S, Bivona B, Harrison-Bernard L
Am J Physiol Renal Physiol
. 2007 Apr;
293(1):F60-7.
PMID: 17409281
Angiotensin type 1A (AT(1A)) and 1B (AT(1B)) receptor deletion (AT1DKO) results in renal microvascular disease, tubulointerstitial injury, and reduced blood pressure. To test the hypothesis that renal preglomerular responses to...